May 2021
May 20, 2021 (WASHINGTON) – Today, Rep. Bennie G. Thompson (D-MS), Chairman of the Homeland Security Committee, and Rep. Carolyn B. Maloney (D-NY), Chairwoman of the Oversight and Reform Committee, released the below statement on news that Homeland Security Secretary Alejandro Mayorkas has ordered U.S. Immigration and Customs Enforcement (ICE) to sever its ties with the Irwin County Detention Center (ICDC) in Georgia, an ICE facility run by LaSalle Corrections.
Washington, D.C. (May 19, 2021)—Today, Rep. Carolyn B. Maloney, the Chairwoman of the Committee on Oversight and Reform, issued this statement following her vote to establish an independent, bipartisan 9/11-type commission to examine the attack on the United States Capitol on January 6, 2021:
Washington, D.C. (May 19, 2021) – Today, the Select Subcommittee on the Coronavirus Crisis, chaired by Rep. James E. Clyburn, held a hybrid hearing with Emergent BioSolutions, Inc.'s (Emergent) President and Chief Executive Officer, Robert G. Kramer, and Executive Chairman, Fuad El-Hibri.
Washington D.C. (May 19, 2021)—Today, Oversight and Reform Committee Chairwoman Carolyn B. Maloney, Ranking Member James Comer, Government Operations Subcommittee Chairman Gerald E. Connolly, and Committee Member Virginia Foxx issued the following statements:
Washington, D.C. (May 19, 2021)—At today's Select Subcommittee on the Coronavirus Crisis hearing examining Emergent Biosolutions's multi-million-dollar contracts to produce vaccines, Oversight and Reform Committee Chairwoman Carolyn B. Maloney questioned Emergent's CEO Robert Kramer. Mr. Kramer admitted under questioning that the United States has been unable to use any coronavirus vaccines the company has produced due to contamination issues—despite the fact that the federal government has already paid Emergent more than $271 million. Mr.
Washington, D.C. (May 19, 2021)—Below is Committee on Oversight and Reform Chairwoman Carolyn B. Maloney's opening statement, as prepared for delivery, for today's hybrid hearing with Emergent BioSolutions' executives.